Genetically Modified L3,7 and L2 Lipooligosaccharides from Neisseria meningitidis Serogroup B Confer a Broad Cross-Bactericidal Response

Currently available Neisseria meningitidis serogroup B (MenB) vaccines are based on outer membrane vesicles (OMVs) that are obtained from wild-type strains. They are purified with the aim of decreasing the lipooligosaccharide (LOS) content and hence reduce the reactogenicity of the vaccine even thou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infection and Immunity 2009-05, Vol.77 (5), p.2084-2093
Hauptverfasser:	Weynants, V, Denoël, P, Devos, N, Janssens, D, Feron, C, Goraj, K, Momin, P, Monnom, D, Tans, C, Vandercammen, A, Wauters, F, Poolman, Jan T
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Bacterial - blood Bacteriology Biological and medical sciences Female Fundamental and applied biological sciences. Psychology Gene Knockout Techniques Lipopolysaccharides - genetics Lipopolysaccharides - immunology Mice Microbial Immunity and Vaccines Microbial Viability Microbiology Miscellaneous Neisseria meningitidis Neisseria meningitidis, Serogroup B - chemistry Neisseria meningitidis, Serogroup B - immunology Porins - genetics Secretory Vesicles - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Currently available Neisseria meningitidis serogroup B (MenB) vaccines are based on outer membrane vesicles (OMVs) that are obtained from wild-type strains. They are purified with the aim of decreasing the lipooligosaccharide (LOS) content and hence reduce the reactogenicity of the vaccine even though LOS is a potential protective antigen. In
ISSN:	0019-9567 1098-5522
DOI:	10.1128/IAI.01108-08